Cytauxzoonosis felis, a tick-borne protozoal infection affecting both domestic and wild cats, originates from the hemoprotozoan parasite Cytauxzoon felis. This condition is characterized by severe hemolytic anemia, often resulting in a mortality rate as high as 90%. Notably, wild cats, specifically bobcats, act as natural reservoirs for this disease.
Currently, the infection is widespread in regions of the central, south-central, south-eastern, and mid-Atlantic United States. The geographic reach of ticks capable of transmitting the disease is expanding due to climate change and associated weather changes. Cats exposed to outdoor environments or living in households with other pets venturing outdoors face an elevated risk of infection. Wooded locations that are natural habitats of bobcats and have large numbers of ticks are particularly susceptible.
Clinical signs typically start about 10 days post-tick bite, initially presenting as vague and non-specific. Acute symptoms include lethargy, loss of appetite, dyspnea, and pale or yellow gums. Invasion of reticuloendothelial cells in various organs leads to organomegaly, with cats displaying signs of aversion to touch due to pain. Bone marrow involvement may result in pancytopenias, and thrombocytopenia can lead to disseminated intravascular coagulation, causing spontaneous bleeding.
As parasites multiply in the blood and disseminate throughout the body, untreated cases progress rapidly, with death possible within two to three days post-fever spike. In advanced stages, hypothermia, seizures, or coma may manifest.
Diagnosis involves a blood smear examination for piroplasms, molecular detection using PCR, and serological tests. In the absence of piroplasms or schizonts on a blood smear, rapid diagnosis can be pursued through fine-needle aspiration of a peripheral lymph node, spleen, or liver to identify schizonts cytologically. A diagnostic PCR test, with greater sensitivity and specificity than microscopy, is recommended in suspect cases or when the parasite is not observed.
Immune-mediated hemolytic anemia, cholangiohepatitis, and FIP should be considered as differentials.
Regrettably, no curative therapy exists. Treatment primarily focuses on supportive care, including IV fluids for tissue perfusion, blood transfusions to address anemia, and heparin therapy for disseminated intravascular coagulation. Anti-protozoal medications, such as imidocarb and a combination of azithromycin and atovaquone, have shown varying success. A significant case series reported a 64% survival rate with atovaquone and azithromycin combination therapy.
Recovery, including resolution of fever, is often slow and may take up to 5–7 days. Survivors may remain persistently infected with piroplasms, potentially representing a reservoir of infection.
Unfortunately, due to the lack of effective therapy, the prognosis remains poor to grave.
Several critical considerations highlight the complexity of cytauxzoonosis felis:
– Survivors remain chronically parasitemic but clinically asymptomatic.
– Immunity to subsequent infections has been observed in survivors.
– C. felis infection is limited to the cat family, posing no risk to humans, dogs, or other species.
– Ongoing research is pivotal for the development of a vaccine against cytauxzoonosis felis.
In conclusion, a comprehensive understanding of this life-threatening disease is crucial for veterinarians and cat owners. Collaborative efforts, including effective preventive measures and ongoing research, are essential to mitigate the impact of cytauxzoonosis felis on feline populations.